Hints and tips:
...Rova-T, a treatment for solid tumours, targets cancer stem cells....
...At the time of the Stemcentrx acquisition, AbbVie said it was aiming to start selling Rova-T in 2018, and predicted it would generate several billion dollars in global sales at its peak....
...Target: Pharmacyclics Inc | Acquirer: AbbVie Deal value $21bn | Premium 61% No auction was more hotly contested than that of Pharmacyclics, which made a single drug, Imbruvica, for blood cancer....
...Rova-T adopts a novel approach whereby a toxic agent is delivered directly into the tumour cell so it can kill the cancer without destroying healthy tissues as well....
...Stemcentrx, recently acquired by AbbVie for $5.8bn, will present data from a study of its drug, Rova-T....
...Richard Gonzalez, chief executive of Abbvie, said: The addition of Stemcentrx and its late-stage compound Rova-T provide AbbVie with a unique platform in solid tumor therapeutics and complement our leadership...
...Stemcentrx’s most advanced drug is Rova-T, which targets a tumour cell protein that is found in more than 80 per cent of those suffering from a type of lung cancer known as “small cell”....
International Edition